Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease .
10 United States sites
4 Tunisia sites
3 Lebanon sites
1 Greece site
1 Italy site
1 Netherlands site
1 Oman site
18 to 65 Years
HbSS
Phase 2
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.
61 France site
5 Germany sites
4 French Guiana sites
4 Italy sites
2 Guadeloupe sites
2 Martinique sites
1 Greece site
> 2 Years
The goal of the study is to compare the efficacy and safety of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.
6 United States sites
5 Brazil sites
3 Italy sites
3 Spain sites
3 Turkey sites
2 France sites
2 Greece sites
2 United Kingdom sites
1 South Africa site
1 Netherlands site
> 16 Years
HbSS
Phase 2
This is a multi-site, observational study to evaluate the long-term safety and efficacy of CTX001 in subjects who received CTX001 in Study CTX001-111 (NCT03655678) or Study CTX001-121 (NCT03745287).
5 United States sites
1 Italy site
1 Germany site
> 18 Years
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.
9 Brazil sites
9 United States sites
6 United Kingdom sites
5 Italy sites
5 Belgium sites
5 Germany sites
4 Spain sites
3 Netherlands sites
3 India sites
3 Greece sites
3 Colombia sites
3 France sites
2 Turkey sites
2 Canada sites
2 Panama sites
2 Lebanon sites
1 South Africa site
1 Jordan site
1 Ghana site
1 Finland site
1 Oman site
> 12 Years
Phase 3
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.
16 United States sites
5 Nigeria sites
4 Egypt sites
3 Italy sites
3 Kenya sites
3 United Kingdom sites
2 Oman sites
2 Ghana sites
2 Saudi Arabia sites
2 to 14 Years
Phase 3
Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials .
24 United States sites
6 United Kingdom sites
4 Egypt sites
3 Kenya sites
3 Turkey sites
2 Lebanon sites
2 Netherlands sites
1 Canada site
1 France site
1 Oman site
1 Italy site
> 12 Years
Phase 3
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
1 Italy site
1 Saudi Arabia site
1 to 18 Years
Phase 1/Phase 2
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.
19 United States sites
5 Spain sites
4 Belgium sites
3 Brazil sites
3 Colombia sites
3 India sites
3 Italy sites
2 Canada sites
2 Germany sites
2 Lebanon sites
2 Turkey sites
2 United Kingdom sites
1 Oman site
1 Switzerland site
1 France site
6 to 17 Years
HbSS, HbSC
Phase 2
This is a single-arm, open-label, multi-site, single-dose Phase 1/2 study in subjects with severe sickle cell disease (SCD).
8 United States sites
1 Belgium site
1 Canada site
1 Germany site
1 Italy site
1 United Kingdom site
12 to 35 Years
Phase 1/Phase 2
